TORONTO (PRWEB) May 02, 2019
Australians have the highest incidence of melanoma in the world. Despite extensive public health efforts, new survival-prolonging therapies and record government spending, the mortality rate of this cancer has steadily increased over the past 50 years. Diagnostic imprecision of up to 48 percent and a lack of standardised molecular biomarkers are two factors that are thought to be contributing to Australia’s ongoing melanoma epidemic. As such, there is an urgent need for new, accurate and non-invasive methods to detect, diagnose and monitor this disease.
To identify a signature of cutaneous melanoma that can be detected in both solid tissue and blood, NanoString® miRNA expression profiling was chosen because the NanoString nCounter platform works with small amounts of starting material, is cost-effective and scalable, and has built-in QC and normalization features.
Join Ryan Van Laar, Ph.D., Founder & CEO, Geneseq Biosciences in a live webinar on Tuesday, May 21, 2019 at 5pm EDT to learn about:
- Detection of malignant melanoma using NanoString miRNA expression profiling system
- Comparison of different microRNA analysis platforms
- Evaluation of normalization and classification algorithms
- Molecular and function pathway analyses
- Geneseq Biosciences’ ongoing technical and clinical validation work
For more information or to register for this event, visit Development and Clinical Translation of Melaseq™.
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.